N@N

Market Maker Surveillance Report. BSDM, INHX, CRME, PRPH, PNSN, HKN, Winning Stocks With Lowest Price Friction For Monday, Nov

November 21, 2011 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Monday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Monday there were 3479 companies with "abnormal" market making, 1143 companies with positive Friction Factors and 5445 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Monday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. BSD MEDICAL CORP (NASDAQ:BSDM), INHIBITEX INC (NASDAQ:INHX), CARDIOME PHARMA CORP (NASDAQ:CRME), PROPHASE LABS INC (OTC:PRPH), PENSON WORLDWIDE INC (NASDAQ:PNSN), HKN INC (AMEX:HKN). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     BSDM       $0.450       17.18%       415,062         50.81%       400,694         49.05%       14,368          319     
     INHX       $1.690       18.92%       5,174,530       50.44%       4,909,757       47.86%       264,773         1,567   
     CRME       $0.390       19.21%       83,937          55.54%       67,194          44.46%       16,743          429     
     PRPH       $0.180       14.29%       68,676          57.62%       48,171          40.42%       20,505          1,139   
     PNSN       $0.200       19.42%       332,944         60.55%       216,919         39.45%       116,025         5,801   
     HKN        $0.370       17.29%       81,127          33.04%       59,346          24.17%       21,781          589     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows BSDM with a dollar gain Monday of $0.45000 and a Friction Factor of 319 shares. That means that it only took 319 more shares of buying than selling to move BSDM higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

BSD MEDICAL CORP (NASDAQ:BSDM) - BSD Medical Corporation develops, manufactures, markets, and services systems to treat cancer and diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. The company develops technology and products for thermal ablation and hyperthermia cancer therapy through various techniques, which include thermal ablation that ablates soft tissues at high temperatures through focused microwave energy; superficial hyperthermia, which non-invasively treats cancerous tumors located within a few centimeters of the surface of the body, such as melanoma and recurrent breast cancer; internal or interstitial hyperthermia that treats tumors in combination with internal radiation therapy by inserting tiny microwave antennae that deliver hyperthermic microwave energy to tumors through the same catheters used to deliver radioactive materials to tumors for radiation therapy; and deep hyperthermia, which non-invasively treats tumors located deep within the body. It offers MicroThermX-100 and MicroThermX-180 microwave ablation systems for the ablation of soft tissue; BSD-500 systems that deliver superficial or interstitial hyperthermia therapy or both; and BSD-2000 family of products that non-invasively deliver localized therapeutic heating to solid tumors by applying RF energy to certain cancerous tumors, as well as BSD-2000/3D and BSD-2000/3D/MR. The company serves clinics, hospitals, and institutes that treat cancer in the United States, Europe, and Asia. BSD Medical Corporation was founded in 1978 and is based in Salt Lake City, Utah.

INHIBITEX INC (NASDAQ:INHX) - Inhibitex, Inc., a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections, primarily shingles and chronic infections caused by hepatitis C virus (HCV). Its antiviral product candidates include FV-100, an orally available nucleoside analogue prodrug, which is in Phase II trials for the treatment of herpes zoster or shingles; and INX-189, a HCV nucleoside polymerase inhibitor that has completed preclinical studies for the treatment of chronic hepatitis C infection. The company is also developing anti-bacterials, including Staphylococcal Vaccine, which is in Phase I trial to prevent S. aureus infections; and Aurexis, a humanized monoclonal antibody that has completed Phase II trials for the treatment of S. aureus bloodstream infections in hospitalized patients. It has a license and collaboration agreement with Wyeth Pharmaceuticals for the development of active vaccines against staphylococcus from MSCRAMM protein platform. Inhibitex, Inc. was founded in 1994 and is based in Alpharetta, Georgia.

CARDIOME PHARMA CORP (NASDAQ:CRME) - Cardiome Pharma Corp., a life sciences company, engages in developing proprietary drugs to treat or prevent cardiovascular and other diseases. The company offers BRINAVESS, a product approved for marketing in the European Union, Iceland, and Norway for the conversion of recent onset atrial fibrillation to sinus rhythm in adults. It also has clinical programs, which focuses on the treatment of atrial fibrillation, an arrhythmia (or abnormal rhythm) of the upper chambers of the heart. The company has a phase 1 program for GED-aPC, an engineered analog of recombinant human activated Protein C that completed phase I clinical trials for the treatment of infectious disease. In addition, Cardiome Pharma Corp. has pre-clinical projects that focus on cardiac diseases, ion channel conditions, and other indications. It also has a collaboration and license agreement with Merck & Co., Inc. (Merck), for the development and commercialization of vernakalant; and Astellas Pharma US, Inc. to develop, make, and sell intravenous or injectable formulations of vernakalant in North America. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is headquartered in Vancouver, Canada.

PROPHASE LABS INC (OTC:PRPH) - ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) cold remedy and consumer products, natural base health products, and other supplements and cosmeceuticals for human and veterinary use in the United States. Its products include Cold-EEZE, an OTC zinc gluconate glycine formulation available in lozenge and sugar-free tablet form, which is used to reduce the duration and severity of the common cold. The company also focuses on the research and development of natural base health products, including compounds QR-333 for the topical symptomatic relief of diabetic peripheral neuropathy; QR-440 for the relief of inflammation and joint pain; and QR-448 for the relief of infectious bronchitis in poultry. It distributes its products through food, multi-outlet pharmacy, and chain drug stores; large wholesalers and mass merchandisers; and national broker, distributor, and representative agreements. ProPhase Labs, Inc. has a joint venture with Phosphagenics Inc. to develop and commercializ a range of non-prescription remedies using TPM technology. ProPhase Labs, Inc. was formerly known as The Quigley Corporation and changed its name to ProPhase Labs, Inc. in May 2010. ProPhase Labs, Inc. was incorporated in 1989 and is headquartered in Doylestown, Pennsylvania.

PENSON WORLDWIDE INC (NASDAQ:PNSN) - Penson Worldwide, Inc., through its subsidiaries, provides various critical securities and futures processing infrastructure products and services to the financial services industry. Its products and services include securities and futures clearing and execution, clearing and custody services, trade settlement, technology services, risk management services, and customer account processing and customized data processing services, as well as financing and cash management technology and other related products. The company also participates in margin lending, securities borrowing, and lending transactions, primarily to facilitate clearing and financing activities, as well as provides tools and services to support trading in multiple markets, asset classes, and currencies. In addition, it offers Internet account portfolio information, holding and safeguarding securities and cash deposits, securities lending and borrowing, proprietary trading, futures products, and institutional and active retail front-end trading software products and services, as well as technology and data product offerings, including customizable front-end trading platforms, options and futures trade data, and order-management services. It serves online, direct access, and traditional retail brokers, as well as banks, institutional brokers, financial technology companies, and securities exchanges in the United States, Canada, Europe, and Asia. The companys securities and futures processing infrastructure products and services are marketed principally under the Penson name. Penson Worldwide, Inc. was founded in 1995 and is headquartered in Dallas, Texas.

HKN INC (AMEX:HKN) - HKN, Inc., together with its subsidiaries, engages in the exploration, exploitation, development, and production of crude oil and natural gas properties primarily in the onshore and offshore Gulf Coast regions of south Texas and Louisiana. The company also explores and develops coal bed methane in Indiana and Ohio. As of December 31, 2009, it operated or owned a non-operating working interest in 69 oil wells, 65 gas wells, and 12 injection wells. The company was founded in 1973 and is based in Southlake, Texas.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net